



- (51) **International Patent Classification:**  
*C07D 471/20* (2006.01) *A61P 25/00* (2006.01)  
*A61K 31/4985* (2006.01)
- (21) **International Application Number:**  
PCT/US2012/023593
- (22) **International Filing Date:**  
2 February 2012 (02.02.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/438,685 2 February 2011 (02.02.2011) US  
61/440,987 9 February 2011 (09.02.2011) US  
61/495,538 10 June 2011 (10.06.2011) US
- (71) **Applicant (for all designated States except US):** VERTEX  
PHARMACEUTICALS INCORPORATED [US/US];  
130 Waverly Street, Cambridge, MA 02139 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** HADIDA RUAH,  
Sara, S. [US/US]; 2356 Torrey Pines Road, #16, La Jolla,  
CA 92037 (US). KALLEL, Edward, Adam [US/US];  
10160 Boulder Knolls Drive, Escondido, CA 92026 (US).  
MILLER, Mark, Thomas [US/US]; 5075 La Jolla  
Boulevard 9, San Diego, CA 92109 (US). ARUMUGAM,  
Vijayalaksmi [US/US]; 506 Camino De La Paz, San Mar-  
cos, CA 92078 (US). MCCARTNEY, Jason [US/US];  
2212 Carol View Drive, Apt. 114, Cardiff By The Sea, CA  
92007 (US). ANDERSON, Corey [US/US]; 7565 Char-  
mant Drive, Unit 502, San Diego, CA 92122 (US).  
GROOTENHUIS, Peter, Diederik Jan [NL/US]; 4801  
Riding Ridge Road, San Diego, CA 92130 (US). JIANG,  
Licong [US/US]; 8305 Stage Coach Place, San Diego, CA  
92129 (US).

- (74) **Agents:** ALI, Bashir, M. et al.; Brinks Hofer Gilson & Li-  
one, P. O. Box 110285, Research Triangle Park, NC 27709  
(US).

- (81) **Designated States (unless otherwise indicated, for every  
kind of national protection available):** AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,  
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States (unless otherwise indicated, for every  
kind of regional protection available):** ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU,  
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,  
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,  
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a  
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii))

**Published:**

- with international search report (Art. 21(3))

(54) **Title:** PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS

(57) **Abstract:** The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

